NJ
NJ Flexi Cap Fund Direct Growth
Latest NAV
-5.38% 1Y
Sign In to Add to Portfolio
Benchmark: Nifty 500 TRI
Expense ratio
0.92%
AUM
₹2,697 Cr
Min SIP
₹100
Min lump sum
₹500
1Y
-5.38%
3Y (ann.)
+8.73%
5Y (ann.)
+0.00%
Launched
Sep 2023
Where the NAV sits & how risky it is
₹13.03
52-week range
at 49%
₹13.03
Low 30 Mar 2026₹12.03
High 07 Jan 2026₹14.09
Risk level
Very High
Low
Very high
NAV history
06 Sep 2023
Since inception
05 Oct 2026
Returns by period
1W
-2.69%
1M
-5.52%
3M
-2.55%
6M
+6.12%
1Y
-5.38%
3Y
+8.73%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹100
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 96.91%
Cash & other 7.28%
Sector split
Country split
Top 5 hold 20.8%
Top 10 hold 39.4%
50 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Marico
INE196A01026 |
Consumer Defensive Household & Personal Products |
India |
4.42%
|
+8.02% |
| 2 | Eicher Motors
INE066A01021 |
Consumer Cyclical Auto Manufacturers |
India |
4.23%
|
-1.82% |
| 3 | Britannia Industries
INE216A01030 |
Consumer Defensive Packaged Foods |
India |
4.11%
|
-15.22% |
| 4 | Bosch
INE323A01026 |
Consumer Cyclical Auto Parts |
India |
4.05%
|
+4.23% |
| 5 | Dr. Lal Path Labs
INE600L01024 |
Healthcare Diagnostics & Research |
India |
3.97%
|
+7.72% |
| 6 | ICICI Bank
INE090A01021 |
Financial Services Banks - Regional |
India |
3.96%
|
-1.93% |
| 7 | Cipla
INE059A01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.79%
|
-7.61% |
| 8 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.69%
|
+19.75% |
| 9 | ITC
INE154A01025 |
Consumer Defensive Tobacco |
India |
3.67%
|
-26.33% |
| 10 | Dr Reddys Laboratories
INE089A01031 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.53%
|
+0.36% |
About this scheme
The investment objective of the Scheme is to generate long term capital appreciation by investing in equity and equity related instruments across market capitalizations. However, there is no assurance or guarantee that the investment objective of the scheme will be achieved.
Fund manager(s): Dhaval Patel, Viral Shah, Jaimin Illavia
Exit load: No charges for withdrawal
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
06 Sep 2023
Lump-sum min
₹500
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 126.9 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 38.8 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 36.0 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 36.0 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 34.6 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 34.5 pts ahead of this fund